Transaction Details

Footnotes

This Form 4 is being amended to correct the reporting of the Reporting Persons November 28, 2025 transaction. Due to an administrative error, the original Form 4 inadvertently reported the exercise of 5,970 stock options. The transaction actually consisted of the exercise of 12,830 stock options. | Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. | This line is included solely to report the Reporting Persons corrected beneficial ownership of Common Stock in Column 5 following the November 28, 2025 transactions previously reported in the Form 4 filed on December 2, 2025. | The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026.